Novo Holdings

Novo Holdings plans to elect Lars Green, former CFO of Novozymes (now Novonesis), as Chair, and Britt Meelby Jensen, CEO of Ambu A/S, as Vice Chair. They will succeed Lars Rebien Sørensen and Steen Riisgaard, who have served as Chair and Vice Chair since 2018.   Lars Green says:   “I look forward to taking on the responsibility as Chair of Novo Holdings and to work with the rest of the Board, CEO Kasim Kutay, and the rest of the management team on strengthening and expanding the important work of Novo Holdings. Our purpose is to create attractive returns that enable our owner, the Novo Nordisk Foundation, to continue and increase its grant-giving activities to the benefit of people and the planet.”   The planned changes to the Board will come into effect in November 2025. Read more here: https://lnkd.in/dbpZndAw

We are looking for a Student Assistant to support the Legal team in transactions, asset management and various internal matters out of our Copenhagen office. As a Student Assistant you will undertake varying and challenging tasks in relation our deliveries, the fulfillment of key legal strategic initiatives and goals, as well as the day-to-day operations of the organisation https://lnkd.in/dJWPNCc8

Novo Holdings has co-led a €40 million financing round for Matr Foods alongside new investor EIFO and the European Investment Bank (EIB).   We first invested in MATR in 2024 and are pleased to continue supporting its scale-up — including a new 4,000-tonne production facility in Jutland, Denmark — to meet growing demand for organic, fungi-fermented meat alternatives that are both nutritious and have a low carbon footprint.   The investment was made through Novo Holdings’ Planetary Health Investments team, which backs companies developing technologies and solutions that advance the green transition.

Novo Holdings portfolio company Nalu Medical, Inc., today announced it entered into an agreement to be acquired by Boston Scientific.   The Nalu Neurostimulation System is designed to deliver targeted relief for adults living with severe, intractable chronic pain of peripheral nerve origin, including areas such as the shoulder, lower back and knee, through peripheral nerve stimulation (PNS). Nalu’s COMFORT RCTs have demonstrated significant and durable pain reduction in patients with peripheral nerve pain.   Novo Holdings led Nalu Medical’s Series E financing in January 2024. Learn more about the transaction: https://lnkd.in/eNnryF6N #medtech #ventureinvestments

Congratulations to Expedition Therapeutics, on the closing of their $165 million oversubscribed Series A financing. Novo Holdings co-led the financing, which will support the advancement of the company's lead candidate, EXPD-101, a once-daily, oral DPP1 inhibitor, through a global Phase 2 program in chronic obstructive pulmonary disease (COPD).    Learn more about Expedition and the unmet need for COPD therapies here: https://lnkd.in/eSK_JaA6 #VentureInvestments #InvestorsinLifeSciences 

Last week in Singapore, Novo Holdings signed a Memorandum of Understanding with the Singapore Economic Development Board (EDB), SG Growth Capital, and MPM BioImpact, to establish the Singapore Biotech Bridge, a new initiative designed to connect innovative biotech companies from Asia with Singapore’s research, capital, and global industry networks.   The collaborations will anchor and support biotech ventures, enabling them to accelerate drug development and strengthen international connectivity from Singapore. Partner VCs, including SG Growth Capital and MPM BioImpact, will also contribute mentorship, scientific and business guidance, and potential investment pathways to support participating companies.   At Novo Holdings, we are committed to supporting life science innovation globally, and we look forward to working with our partners to make the Singapore Biotech Bridge a catalyst for regional biotech growth and collaboration. #LifeSciences #Biotech #Innovation #Asia #Singapore #NovoHoldings

Halozyme, Inc. has announced it will acquire Novo Holdings portfolio company Elektrofi. Novo Holdings co-led Elektrofi’s Series C financing in 2024, and we are pleased that Elektrofi’s innovative technology will continue on its next chapter of drug delivery solutions.   Elektrofi’s Hypercon™ microparticle technology enables biologic product formulation concentrations of 400-500 mg/ml, which can be up to 4 to 5 times higher than standard aqueous solution formulations for biologics today, all while maintaining the ability to inject smoothly and easily – creating more opportunities to deliver biologic therapies to patients.   Learn more about Elektrofi and Halozyme here: https://lnkd.in/eduRew9V #GrowthInvestments #InvestorsinLifeSciences

Novo Holdings is pleased to act as a cornerstone investor in the launch of 55 North, the world’s largest dedicated quantum fund. 55 North today announced the first close of €134 million in its €300 million Fund I, backed by cornerstone investors Novo Holdings and EIFO. Headquartered in Copenhagen, 55 North will take a stage-agnostic approach to investing in quantum technologies, accelerating their journey from lab to global markets.   Quantum innovation holds the potential to address some of the most critical challenges in human and planetary health, and this marks an important step in strengthening the Nordic and European quantum ecosystem. https://lnkd.in/dRsyrtuk

Together with current Novo Advisory Group member Jean-Luc Butel, Li Bing and Ajay Bakshi will contribute to the expansion of Novo Holdings’ Asia investment activities.

As a co-founding investor in Crystalys Therapeutics, we are pleased to co-lead the company’s $205 million Series A financing.    The financing will support Phase 3 development of dotinurad, Crystalys’ once-daily oral URAT1 inhibitor with potential to provide an important new treatment option for patients living with gout. Dotinurad has already received several regulatory approvals across Asia and has treated more than 1.2 million patients since 2020.    Learn more about Crystalys and its potential to transform the treatment of gout on a global scale: https://lnkd.in/e5YTrZgS #ventureinvestments #investorsinlifesciences